World Journal of Urology

, Volume 26, Issue 3, pp 231–236 | Cite as

The role of lymphadenectomy in high risk prostate cancer

Topic Paper
First Online:
Received:
Accepted:

Abstract

Historically, patients with high risk prostate cancer were considered poor candidates for radical prostatectomy (RP) due to the likelihood of positive pelvic lymph nodes and decreased long term survival. Although there is still no consensus on the optimal therapy for this group of patients, there is increasing evidence that surgery could play a role. Cancer specific survival (CSS) rates after RP for locally advanced disease at 10 year follow up range from 29 to 72%, depending on tumor differentiation. The role of pelvic lymph node dissection (PLND) in prostate cancer remains a controversial topic. Nonetheless, in conjunction with RRP extended PLND (ePLND) should be performed as extended lymph node dissection in lieu of standard PLND may increase staging accuracy, influence decision making with respect to adjuvant therapy and possibly impact outcome. High risk patients with organ confined prostate cancer and low volume (micro)metastatic disease may be the ones to profit most from this approach.

Keywords

High risk prostate cancer Lymphadenectomy Nodal metastases Radical prostatectomy 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr et al (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32:385–390PubMedGoogle Scholar
  2. 2.
    Khan MA, Mangold LA, Epstein JI, Boitnott JK, Walsh PC, Partin AW (2004) Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol 172:1835–1839PubMedCrossRefGoogle Scholar
  3. 3.
    Lerner SE, Blute ML, Zincke H (1995) Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154:1447–1452PubMedCrossRefGoogle Scholar
  4. 4.
    van den Ouden D, Hop WC, Schroder FH (1998) Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392–1397PubMedCrossRefGoogle Scholar
  5. 5.
    Messing E, Manola J, Sarosdy M, Wilding G, Crawford D, Trump D (2003) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer; results at 10 years of EST 3886. J Urol 169:396Google Scholar
  6. 6.
    D’Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW (2000) Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. Jama 284:1280–1283PubMedCrossRefGoogle Scholar
  7. 7.
    Scardino P (2005) Update: NCCN prostate cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 3(Suppl 1):S29–S33PubMedGoogle Scholar
  8. 8.
    Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD et al (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131PubMedCrossRefGoogle Scholar
  9. 9.
    Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499 (discussion 499)PubMedCrossRefGoogle Scholar
  10. 10.
    D’Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56–61PubMedCrossRefGoogle Scholar
  11. 11.
    Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521–1527PubMedCrossRefGoogle Scholar
  12. 12.
    Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ (2007) Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology 70:685–690PubMedCrossRefGoogle Scholar
  13. 13.
    Bader P, Spahn M, Huber R, Echtle D, Frohneberg D (2004) Limited lymph node dissection in prostate cancer may miss lymph node metastasis and determines outcome of apparently pN0 prostate cancer. Eur Urol 3:16 (A 55)Google Scholar
  14. 14.
    Joslyn SA, Konety BR (2006) Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68:121–125PubMedCrossRefGoogle Scholar
  15. 15.
    Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98:788–793PubMedCrossRefGoogle Scholar
  16. 16.
    Mattei A, Fuechsel FG, Dhar NB, Warncke SH, Thalmann GN, Krause T, Studer UE (2007) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125PubMedCrossRefGoogle Scholar
  17. 17.
    Borley N, Fabrin K, Sriprasad S, Mondaini N, Thompson P, Muir G, Poulsen J (2003) Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high-risk” prostate cancer compared to MRI or CT. Scand J Urol Nephrol 37:382–386PubMedCrossRefGoogle Scholar
  18. 18.
    Cabanas RM (1977) An approach for the treatment of penile carcinoma. Cancer 39:456–466PubMedCrossRefGoogle Scholar
  19. 19.
    Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R (2001) Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol 166:1715–1719PubMedCrossRefGoogle Scholar
  20. 20.
    Bader P, Burkhard FC, Markwalder R, Studer UE (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518 (discussion 518)PubMedCrossRefGoogle Scholar
  21. 21.
    Heidenreich A, Varga Z, Olbert P, Hofmann R (2001) Radical pelvic lymphadenectomy in clinically localised prostate cancer: high frequency of atypical metastasis. Eur Urol 39(suppl. 5):135 (A 530)Google Scholar
  22. 22.
    Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M (2004) Validity of sentinel lymph node concept for patients with prostate cancer. J Urol 171:2268–2271PubMedCrossRefGoogle Scholar
  23. 23.
    Mattei A, Fuechsel FG, Warncke S, Z’Brun S, Baermann C, Krause TM, Studer UE (2005) Advantages of preoperative imaging with Technetium-99m-nanocolloid for prostate-sentinel-lymph-node-adenectomy: accuracy and surgical detection time using presurgical imaging guidance prior to gamma-probe-detection versus gamma-probe detection alone. J Urol 173:433CrossRefGoogle Scholar
  24. 24.
    Gronau E, Weckermann D, Harzmann R (2005) Sentinel lymph node resection in prostate cancer patients with a PSA higher than 20 ng/ml. J Urol 173:437Google Scholar
  25. 25.
    Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499PubMedCrossRefGoogle Scholar
  26. 26.
    Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686PubMedCrossRefGoogle Scholar
  27. 27.
    Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Markl B, Gordijn R, Harzmann R (2003) The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol 43:132–137PubMedCrossRefGoogle Scholar
  28. 28.
    Stone NN, Stock RG, Unger P (1997) Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 158:1891–1894PubMedCrossRefGoogle Scholar
  29. 29.
    Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N, Smith JA Jr (2003) Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 169:145–147 (discussion 147–148)PubMedCrossRefGoogle Scholar
  30. 30.
    DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML (2005) The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173:1121–1125PubMedCrossRefGoogle Scholar
  31. 31.
    Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, Eastham JA, Scardino PT (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320–1324 (discussion 1324–1325)PubMedCrossRefGoogle Scholar
  32. 32.
    Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, Unger P, Tunn U, Kaisary A, Droller M et al (2006) Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 24:3081–3088PubMedCrossRefGoogle Scholar
  33. 33.
    Miyake H, Hara I, Kurahashi T, Inoue TA, Eto H, Fujisawa M (2007) Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 13:1192–1197PubMedCrossRefGoogle Scholar
  34. 34.
    Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, Lieskovsky G, Skinner DG, Cote RJ (2006) Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 24:2735–2742PubMedCrossRefGoogle Scholar
  35. 35.
    Golimbu M, Morales P, Al-Askari S, Brown J (1979) Extended pelvic lymphadenectomy for prostatic cancer. J Urol 121:617–620PubMedGoogle Scholar
  36. 36.
    Catalona WJ, Miller DR, Kavoussi LR (1988) Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy. J Urol 140:540–543PubMedGoogle Scholar
  37. 37.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. Jama 281:1591–1597PubMedCrossRefGoogle Scholar
  38. 38.
    Bader P, Burkhard FC, Markwalder R, Studer UE (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854PubMedCrossRefGoogle Scholar
  39. 39.
    Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864–870 (discussion 870–861)PubMedCrossRefGoogle Scholar
  40. 40.
    Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, Skinner EC, Skinner DG (2004) Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172:2252–2255PubMedCrossRefGoogle Scholar
  41. 41.
    Campbell SC, Klein EA, Levin HS, Piedmonte MR (1995) Open pelvic lymph node dissection for prostate cancer: a reassessment. Urology 46:352–355PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of UrologyUniversity of BernBernSwitzerland

Personalised recommendations